Skip to main content

Advertisement

SpringerLink
Log in

Remarkable response to chidamide plus rituximab in an elderly patient with recurrent, chemotherapy-refractory diffuse larger B-cell lymphoma carrying CREBBP mutation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The clinical data supporting the conclusions of this manuscript will be made available by the authors.

References

  1. Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842–858. https://doi.org/10.1056/NEJMra2027612

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, Jiang A, Bagaev A, Plotnikova O, Kotlov N, Johnson CA, Wilson WH, Scott DW, Staudt LM (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37(4):551-568.e514. https://doi.org/10.1016/j.ccell.2020.03.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87(5):953–959. https://doi.org/10.1016/s0092-8674(00)82001-2

    Article  CAS  PubMed  Google Scholar 

  4. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471(7337):189–195. https://doi.org/10.1038/nature09730

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG, Melnick AM (2017) CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov 7(1):38–53. https://doi.org/10.1158/2159-8290.Cd-16-0975

    Article  CAS  PubMed  Google Scholar 

  6. Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, Zhang X, Jin J, Jin Z, Li Z, Qiu L, Dong M, Huang X, Luo Y, Wang X, Wang X, Wu J, Xu J, Yi P, Zhou J, He H, Liu L, Shen J, Tang X, Wang J, Yang J, Zeng Q, Zhang Z, Cai Z, Chen X, Ding K, Hou M, Huang H, Li X, Liang R, Liu Q, Song Y, Su H, Gao Y, Liu L, Luo J, Su L, Sun Z, Tan H, Wang H, Wang J, Wang S, Zhang H, Zhang X, Zhou D, Bai O, Wu G, Zhang L, Zhang Y (2017) Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol 10(1):69. https://doi.org/10.1186/s13045-017-0439-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bakhshi TJ, Georgel PT (2020) Genetic and epigenetic determinants of diffuse large B-cell lymphoma. Blood Cancer J 10(12):123. https://doi.org/10.1038/s41408-020-00389-w

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sun Y, Gao Y, Chen J, Huang L, Deng P, Chen J, Chai KXY, Hong JH, Chan JY, He H, Wang Y, Cheah D, Lim JQ, Chia BKH, Huang D, Liu L, Liu S, Wang X, Teng Y, Pang D, Grigoropoulos NF, Teh BT, Yu Q, Lim ST, Li W, Ong CK, Huang H, Tan J (2021) CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Lett 521:268–280. https://doi.org/10.1016/j.canlet.2021.09.002

    Article  CAS  PubMed  Google Scholar 

  9. Bobrowicz M, Dwojak M, Pyrzynska B, Stachura J, Muchowicz A, Berthel E, Dalla-Venezia N, Kozikowski M, Siernicka M, Miazek N, Zapala P, Domagala A, Bojarczuk K, Malenda A, Barankiewicz J, Graczyk-Jarzynka A, Zagozdzon A, Gabrysiak M, Diaz JJ, Karp M, Lech-Maranda E, Firczuk M, Giannopoulos K, Efremov DG, Laurenti L, Baatout D, Frenzel L, Malinowska A, Slabicki M, Zenz T, Zerrouqi A, Golab J, Winiarska M (2017) HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood 130(14):1628–1638. https://doi.org/10.1182/blood-2016-08-736066

    Article  CAS  PubMed  Google Scholar 

  10. Guan XW, Wang HQ, Ban WW, Chang Z, Chen HZ, Jia L, Liu FT (2020) Novel HDAC inhibitor chidamide synergizes with rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis 11(1):20. https://doi.org/10.1038/s41419-019-2210-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by National Natural Science Foundation of China (grant number 82200214), Key Research and Development Project of Hubei (grants number 2022BCE028), Young and middle-aged talent program of Hubei Education Bureau (grants number Q20222101), Platform Special Fund for Scientific Research of Xiangyang No.1 People’s Hospital (grants number XYY2022P05), and Instructional projects of Hubei Provincial Health and Health Commission (WJ2023F074).

Author information

Authors and Affiliations

  1. Department of Oncology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang, 441000, China

    Dongdong Zhang, Yidi Han & Youhong Dong

Authors
  1. Dongdong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yidi Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Youhong Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DDZ conceived and designed the study. YDH collected and analyzed the data, wrote the manuscript, and revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Dongdong Zhang.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethics and Scientific Committee of Hubei University of Medicine (XYY2021002) and was performed according to the Good Clinical Practice Guidelines and the Helsinki Declaration.

Consent for publication

An informed consent was received from patients authorized representative for publication of identifying information/images in an online open-access publication.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, D., Han, Y. & Dong, Y. Remarkable response to chidamide plus rituximab in an elderly patient with recurrent, chemotherapy-refractory diffuse larger B-cell lymphoma carrying CREBBP mutation. Ann Hematol 102, 1265–1268 (2023). https://doi.org/10.1007/s00277-023-05183-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05183-9

Search

Navigation